Short interest is the total number of shares lent out as per latest regulatory filings. Updated twice a month per FINRA reporting.

Short float is the total number of shares currently held as short positions divided by the total float as per latest regulatory filings. Updated twice a month per FINRA reporting.

Short float

Shorting

Short interest

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Catalyst Pharmaceuticals excels in Q4 2024, eyes rare disease growth

Catalyst Pharmaceuticals delivered strong financial performance in Q4 2024, driven by record revenue growth and robust product sales. The company's focus on strategic growth, operational excellence, and patient impact positions it well for future success and sustainability. While facing challenges in a competitive market, Catalyst has opportunities to capitalize on rare disease prospects and drive continued growth.

Catalyst Pharmaceuticals reports robust Q1 revenue growth and strategic focus

Catalyst Pharmaceuticals demonstrated strong revenue growth and product performance in Q1 2025, driven by key products like FIRDAPSE and AGAMREE. While facing challenges such as FYCOMPA's revenue decline post-patent expiry, the company remains focused on sustaining growth and operational excellence. Strategic initiatives to expand global access to rare disease therapies and pursue business development opportunities position Catalyst for future success. With a reaffirmed full-year revenue guidance and a commitment to patient access, Catalyst Pharmaceuticals shows confidence in its growth trajectory.

Catalyst Pharmaceuticals reports record Q2 revenue, eyes strategic growth

Catalyst Pharmaceuticals delivered a strong performance in Q2 2025, driven by record revenue and strategic initiatives. While facing challenges like FYCOMPA's revenue decline, the company remains focused on long-term value creation. Opportunities in leveraging new leadership, expansion strategies, and innovation can fuel future growth. Overall, Catalyst's financial health, strategic vision, and commitment to growth position it well for the future.

Catalyst Pharmaceuticals excels in Q3, raises guidance and initiates buyback

Catalyst Pharmaceuticals demonstrated strong financial performance in Q3 2025, driven by revenue growth in key products like FIRDAPSE and AGAMREE. While facing challenges such as declining revenue for FYCOMPA, the company remains focused on patient engagement and expanding its rare disease therapies. With an increased revenue guidance, a share buyback program, and a solid cash position, Catalyst is poised for continued growth and value creation. Strategic initiatives and a commitment to innovation position Catalyst well to capitalize on opportunities in the rare disease treatment market and drive sustained growth.

Catalyst Pharmaceuticals (CPRX) reports robust Q4 earnings and growth strategies

Catalyst Pharmaceuticals (CPRX) delivered strong financial results in Q4 2025, driven by revenue growth across key products and exceeded expectations for FYCOMPA. The company's strategic focus on rare disease products and efforts to enhance market uptake and reimbursement rates position it for continued growth. While facing challenges from generic competition and ongoing studies, CPRX remains optimistic about revenue projections and market opportunities in 2026. Overall, CPRX's performance, strengths, challenges, and opportunities reflect a dynamic landscape with potential for sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.